Department of Pharmacology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Biomed Pharmacother. 2020 Sep;129:110486. doi: 10.1016/j.biopha.2020.110486. Epub 2020 Jul 8.
Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis and manifests as a complex and dysregulated immune response. To date, there is no cure for IBD; thus, lifelong administration of maintenance drugs is often necessary. Since conventional IBD treatment strategies do not target the sites of inflammation, only limited efficacy is observed with their use. Moreover, the possibility of severe side effects resulting from systemic drug redistribution is high when conventional drug treatments are used. Therefore, a straightforward disease-targeted drug delivery system is desirable. Based on the pathophysiological changes associated with IBD, novel site-specific targeted drug delivery strategies that deliver drugs directly to the inflammation sites can enhance drug accumulation and decrease side effects. This review summarizes novel inflammation targeted delivery systems in the management of IBD. It also discusses the challenges and new perspectives in this field.
炎症性肠病（IBD）包括克罗恩病和溃疡性结肠炎，表现为复杂和失调的免疫反应。迄今为止，IBD 尚无治愈方法；因此，通常需要终身使用维持药物。由于传统的 IBD 治疗策略并不针对炎症部位，因此使用这些药物的效果有限。此外，当使用传统药物治疗时，由于药物在全身重新分布，严重副作用的可能性很高。因此，需要一种直接针对疾病的药物输送系统。基于与 IBD 相关的病理生理变化，直接将药物递送到炎症部位的新型靶向药物传递策略可以增强药物积累并减少副作用。本综述总结了用于治疗 IBD 的新型炎症靶向药物传递系统。它还讨论了该领域的挑战和新视角。
